Health Catalyst Proposes Board Declassification, Details Executive Severance Amid Restructuring
HCAT sits 33% above its 52-week low of $0.955.
Summary
Health Catalyst proposes to declassify its board, enhancing shareholder rights, while also disclosing significant severance payments to former executives as part of ongoing restructuring efforts.
Key Events · Corporate Governance and Compliance · HCAT
-
Board Declassification Proposed
Shareholders will vote on a proposal to phase out the classified board structure, moving to annual director elections for all directors starting with the 2029 Annual Meeting. This follows an advisory approval in 2025.
-
Significant Executive Severance Packages
Former Chief Commercial Officer Kevin Freeman received approximately $696,833 in cash, health benefits, and accelerated equity vesting. Former Chief Operating Officer Dan LeSueur received approximately $691,211 in cash, health benefits, and accelerated equity vesting. These payouts total approximately $1.38 million.
-
Board Size Reduction and Refreshment
The board is being reduced from seven to six directors, with Matthew Kolb not standing for re-election. The company has also added three new independent directors and appointed a new CEO since the beginning of 2025.
-
Related Party Transactions and Voting Agreement
The company has ongoing technology and professional service relationships with Carle Health, a non-profit hospital network where a former director served as COO, generating $17.7 million in revenue in 2025. Additionally, a voting agreement with First Light Asset Management (a 17.4% owner) and Director Mathew Arens requires them to vote in line with board recommendations, with exceptions.
Analysis · HCAT · Technology
Health Catalyst is seeking shareholder approval to declassify its board, transitioning to annual director elections by 2029, a move generally favored by governance advocates. This comes as the company continues a significant restructuring, including a recent 9% workforce reduction and executive leadership changes. The filing details substantial severance packages for two departing executives, totaling approximately $1.38 million, which represents a notable financial outflow for a company of this market capitalization, especially in the context of recent significant net losses and goodwill impairment.
At the time of this filing, HCAT was trading at $1.27 on NASDAQ in the Technology sector, with a market capitalization of approximately $93.8M. The 52-week trading range was $0.96 to $4.29. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.